Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Women aged 12-55 years who have a uterus and at least one functioning ovary.~Women with any active uterine bleeding more than spotting~Diagnosed with bone marrow failure, and other disease that require treatment with chemotherapy or stem cell transplantation with platelet counts less than 50,000 microliters at study entry~Do not desire pregnancy for the duration of the study.~Willing and able to give informed consent.~Willing and able to comply with study requirements.~EXCLUSION CRITERIA:~Age less than 12 years~Postmenopausal women~Hormone level in menopausal range: Follicle Stimulating Hormone greater than 40 IU/L, E (2) less than 20 pg/ml~History of liver disease that precludes OCP use~History of thrombosis, thromboembolism and/or thrombophilia.~Currently on 2 or more tablets of any oral contraceptive pills per day at study entry~Having 2 or more depo medroxyprogesterone acetate injections in the past 12 months or having depo medroxyprogesterone acetate injection in the past 90 days~Leuprolide acetate injection in the past 30 days~Smoker over the age of 35~Women with estrogen dependent tumor e.g. breast cancer.~Pregnancy.~Underlying sickle cell anemia~Women who are taking chemotherapeutic agents known to cause ovarian failure such as alkylating agents~Allergy to any medication in this protocol

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Lo-ovral (Type: ACTIVE_COMPARATOR): 1 tablet of lo-ovral is administered twice a day
- sugar pill (Type: PLACEBO_COMPARATOR): Sugar pill was provided as a placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).